

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  26D0046398	<b>(X3) Date Survey Completed</b>  04/03/2023
<b>Name of Provider or Supplier</b>  Salem Memorial District Hospital	<b>Street Address, City, State</b>  35629 Hwy 72, Salem, MO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider for 2022/2023 and interview with the technical supervisor (TS) on March 27, 2023 at 10:00 AM , the laboratory failed to successfully participate in PT. Refer to D-tag 2096, unsatisfactory performance in two consecutive Uric Acid PT challenges and two out of three testing events for LDL Cholesterol PT challenges.</p>
<b>D2096</b>	<p>ROUTINE CHEMISTRY CFR(s): 493.841(f)</p>

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider for 2022/2023 and interview with the technical supervisor (TS), the laboratory failed to achieve satisfactory performance for Uric Acid in two consecutive testing events and LDL Cholesterol for two of three testing events.

Findings: 1. Review of the chemistry- core PT results for the third event of 2022 showed the laboratory obtained an unsatisfactory score of 60 percent for the analyte Uric Acid. 2. Review of the chemistry- core PT results for the first event of 2023 showed the laboratory obtained an unsatisfactory score of zero percent for the analyte Uric Acid. 3. Review of the chemistry- core PT results for the second event of 2022 showed the laboratory obtained an unsatisfactory score of 40 percent for the analyte LDL Cholesterol. 4. Review of the chemistry- core PT results for the first event of 2023 showed the laboratory obtained an unsatisfactory score of zero percent for the analyte LDL Cholesterol. 5. Interview with the technical supervisor (TS) on March 27, 2023 at 10:00 AM confirmed the laboratory failed to achieve satisfactory performance for Uric Acid in two consecutive testing events and LDL Cholesterol in two of three testing events.